Policy & Regulation
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
2 May 2025 - Blue Earth Therapeutics, a UK-based developer of radiopharmaceutical therapies, on Thursday reported further progress in the development of its radio-hybrid, lutetium-labelled, PSMA targe...
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
2 May 2025 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American:ARMP) announced on Thursday that it has received an additional USD4.65m of non-dilutive funding pursuant to a previously an...
S&E bio's SNE-101 stroke therapy approved for clinical trial
2 May 2025 - S&E bio Co Ltd, a South Korea-based biotechnology company specialising in exosomal microRNA-based therapies, announced on Thursday that it has received approval from Korea's Mini...
TransCode Therapeutics reports progress in metastatic cancer trial
2 May 2025 - RNA oncology company TransCode Therapeutics Inc (NASDAQ:RNAZ) on Thursday reported further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer.TTX-MC13...
BioArctic receives SEK101.7m in royalties from Q1 Leqembi sales
1 May 2025 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Thursday that its royalties from first-quarter 2025 global sales of Leqembi (lecanemab), developed in partn...
Neurocrine Biosciences initiates NBI-1117568 Phase 3 registrational programme for potential schizophrenia treatment
1 May 2025 - US-based biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) announced on Wednesday the initiation of a Phase 3 registrational programme to evaluate the efficacy, safety an...